NCT00996879View on ClinicalTrials.gov

Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Hepatitis C
Interventions
DRUG

Midazolam

Syrup, Oral, 5 mg, Single dose, 2 days

DRUG

BMS-791325

Capsules, Oral, 300 mg, Every 12 hours, 8 days

Trial Locations (1)

90630

Wcct Global, Llc, Cypress

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00996879 - Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects | Biotech Hunter | Biotech Hunter